Recent Trends in GI - Lung Cancers- Welcome & Introduction

Immune checkpoint Inhibitors in 1L Gastric Cancer GEJC and EAC

PD-1 blockade as curative-intent therapy in mismatch repair deficient locally advanced rectal cancer

Welcome & Introducation

Adjuvant Radiotherapy in Breast Cancer

MBC-To Operate the Primary or Not

Phase 2 Study of Dabrafenib Plus Trametinib in Patients with BRAF V600E Mutant Metastatic NSCLC

Personalized therapy to further improve outcomes in Patients with BRAF Mutated mNSCLC

NSCLC is a heterogeneous set of diseases defined by oncogenic drivers

Oncology Update - Welcome & Introduction

Uncommon Mutations in mNSCLC is it correct to rely on TKY

Neoadjuvant IO in Early Lung Cancer

Welcome & Introduction

Immunotherapy biomarkers in NSCLC

PD-L1 IHC testing landscape in NSCLC